Overview

T-Cell Depleted Double UCB for Refractory AML

Status:
Terminated

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This trial is proposes to build on our experience and is designed to maximize early (day 3-14) and late (day 60-71) donor-derived natural killer (NK) cell expansion and function in vivo. The proposed platform will allow us the unique opportunity to compare in vivo function from a transplanted umbilical cord blood (UCB) source (presumed to contain NK progenitors requiring "education" in the recipient).

Phase:

Phase 2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Allopurinol
Busulfan
Cyclophosphamide
Etiracetam
Fludarabine
Interleukin-2
Levetiracetam